Estimate skeletal muscle mass normalized to height — the primary metric for sarcopenia screening.
Muscle mass is one of the strongest predictors of healthy aging. Low muscle mass — clinically called sarcopenia — is associated with falls, fractures, longer hospital stays, metabolic dysfunction, and higher mortality. SMI is the field standard for quantifying it in a way that's comparable across body sizes.
This equation was derived against MRI-measured skeletal muscle in 388 adults and validated in another 343. It explains about 85% of the variance in muscle mass compared to imaging — accurate enough for screening, not for clinical diagnosis.
| Category | Men (kg/m²) | Women (kg/m²) |
|---|---|---|
| Low (sarcopenic) | < 7.0 | < 5.5 |
| Borderline | 7.0 – 8.5 | 5.5 – 6.2 |
| Average | 8.5 – 10.5 | 6.2 – 8.2 |
| Above average | > 10.5 | > 8.2 |
Full sarcopenia diagnosis (EWGSOP2) requires both low muscle mass and low function — grip strength below 27 kg (men) or 16 kg (women), or gait speed under 0.8 m/s. Strength can drop faster than mass with aging, so a low SMI warrants a functional check too.
An anthropometric estimate can't replace DXA or BIA for clinical sarcopenia diagnosis. If your result flags low muscle mass and you're concerned — particularly if you're over 60 or have had recent unintentional weight loss — bring it to a clinician who can arrange proper body composition testing.
Connect wearable devices and health apps. Get personalized health insights, biological age tracking, and wellness scores with a free Huvolve account.
Create Free Account